>Abituzumab VH (threshold 0.43)
QVQLQQSGAEVNKPGASVKLSCKASGYTFTSFWMHWVRQAPGQGLEWIGYINPRSGYTEYAEIFRDKATLTADKSISTAYMELSSLTSEDSAVYYCARFLGRGAMDYWGQGTSVTVSS
>Abituzumab VL (threshold 0.619)
AIQMTQTTSSLSASVGDRVTISCRASQDISNYLAWYQQKPDKAPKLLIYYTSKIHSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGNTFPYTFGQGTKLEIK
>Afutuzumab VH (threshold 0.83)
QVQLVQSGPEVKKPGASVKVSCKASGYAFSYSWINWVRQAPGQGLEWIGRIFPGDGDTDYAGKFQGKLTLTWDKSTSTAYMHLSSLTSVDSAVYFCARNVFDGYWLVYWGQGTLVTVSS
>Afutuzumab VL (threshold 0.562)
DIVMTQAPFSLPVTLGQSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNRVSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
>Alacizumab VH (threshold 0.935)
QVKLVESGGDLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVSVITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMSSLKVEDTAVYYCARIGEDALDYWGQGTLVTVSS
>Alacizumab VL (threshold 0.6859999999999999)
DIQMTQSPSSLSASLGERVSLTCRASQDIAGSLNWLQQEPDKAPKRLIYATSSLQSGVPKRFSGSRSGSDFSLTISSLQSEDFVTYYCLQYGSFPPTFGQGTKLEIK
>Alemtuzumab VH (threshold 0.835)
QVMLVEWGQGLVQPSGTLSLMCAVSGFTFTDFYWNWVRQPPGKALEWLGFIRDKAKGYTTEYNPSLKGRVTILVDNSQSILSLALNAVTAAESAVYYCAREGHTAAPFDYWGQGSTLTVSS
>Alemtuzumab VL (threshold 0.8420000000000001)
AIKLIQSQASLSASLGDRVTLTCQASQNIDKYLNWYQQKAGKAPKLLVYNTNNLQTGVPSRFSGSGSGTQFTLTINSLQTEDFGNYYCLQHISRPRTFGGGTKVEIK
>Anrukinzumab VH (threshold 0.88)
QVQLVESGGGLVKLGGSLSLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSISSGGNTYYADSVKGRFTISRDNAKNTLYLQMSSLKVEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS
>Anrukinzumab VL (threshold 0.809)
DIQLTQSPSTLSASVGDRATITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLQSGIPSRFSGSGSRTDFTLTINSLQPDDIATYYCQQSNEDPWTFGQGTKLEIK
>Atezolizumab VH (threshold 0.975)
QVQLVESGGGLVQPGRSLGLSCAASGFTFSDSWIHWVRQAPGKGREWVAWISPYGGSTYYADSVKGRFTIFRDVAKNTLYLQMNSLRVEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
>Atezolizumab VL (threshold 0.941)
DIQMTQSHSFMSASVGDRVSITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISNLQPEDLATYFCQQYLYHPATFGGGTKLEIK
>Bapineuzumab VH (threshold 0.97)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQVPGKGLEWVSSIRSGGGRTYYADNVKGRFTISRDNSKNTQYLQMDSLRVEDTAVYYCVRYDHYSGSSDYWGQGTMVTVSS
>Bapineuzumab VL (threshold 0.6579999999999999)
DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWYLQRPGQSPQRLIYLVSKRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKLEIK
>Bemarituzumab VH (threshold 0.745)
QVQLAQSGAEVKKPGASVKMSCKASGYTFTTYNVHWVRQAPGQGLEWMGSIYPDNGDTSYAQNFQGKVTLTADKSSSTAYMELSSLTSEDSAVYYCARGDFAYWGQGTLVTVSA
>Bemarituzumab VL (threshold 0.725)
DIQMTQSHSFMSTSVGDRVSITCRASQGVSNDVAWYQQKPGQAPKLLIYSASYLYTGVPSRFTGSGSGTDFTFTISSLQAEDLATYYCQQHSTTPYTFGGGTKLEIK
>Benralizumab VH (threshold 0.61)
QVQLVQSGPEVNKPGASVKVSCKASGYTFTSYVIHWVRQAPGQGLEWIGYINPYNDGTKYAERFKGKLTLTSDKSISTAYMELSSLTSEDSAVYLCGREGIRYYGLLGDYWGQGTSVTVSS
>Benralizumab VL (threshold 0.981)
DIQMTQSPSSLSASVGDRVTISCGTSEDIINYLNWYQQKPGKAPKLLIYHTSSLQSGVPSRFSGSGSGTDFSLTISNLQPEDIATYFCQQGYTLPYTFGQGTKLEIK
>Bevacizumab VH (threshold 0.81)
QVQLVQSGGNLKKPGETLRISCAASGYTFTNYGMNWVRQAPGKGLKWMSSINTYTGEPTYAASVKRRFAISRETSKNTAYLQINNLKNEDMAVYFCARYPHYYGSSHWYFDVWGHGTTVTVSS
>Bevacizumab VL (threshold 0.899)
DIQMTQSTSSLSASVGDRVTISCQASQDISNYLNWYQQKPGKAPKLLIYFTSSLHSGVPSRFSGSGSGTDFFLTISNLQPEDIATYYCQQYSTVPWTFGGGTKLEIK
>Blosozumab VH (threshold 0.985)
QVQLLQSGAELKRPGASVKVSCAASGFNIKDTFQHWVRQAPGQGLEWMGWSDPEIGDTEYAQKFQGRVTITADTSINTAYMELSSLTSDDTAVYYCTTGDTTYKFDFWGQGTMLTVSS
>Blosozumab VL (threshold 0.8420000000000001)
DIQMTQSHSFLSTSVGDRVSITCRASQDVHTAVAWYQQKPGQAPKLLIYWASTLWTGVPSRFTGSGSGTDFTLTISNLQPDDLATYFCQQYSDYPWTFGGGTKLEIK
>Bococizumab VH (threshold 0.87)
QVQLIQPGAELKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLDWMGEISPFGGRTNYAEKFQSKVTLTVDTSISTAYMELSSLTSEDSAVYYCARERPLYASDLWGQGTSVTVSS
>Bococizumab VL (threshold 0.9009999999999999)
DIQMTQSHSSMSASVGDRVSITCRASQGISSALAWYQQKPGQAPKLLIYSASYLYTGVPGRFTGSGSGTDFTFTISSLQAEDLATYYCQQRYSLWRTFGGGTKLEIK
>Brontictuzumab VH (threshold 0.735)
QVQLIQSGAEVKKPGASVKLSCKATGYTFTGYWIEWVRQAPGHGLEWIGQILPGTGRTNYAEKFQGRATFTADTSITPAYMPLSSLTTEDSAIYYCARFDGNYGYYAMDYWGQGTSVTVSS
>Brontictuzumab VL (threshold 0.72)
QAVVTQEPALTVSPGETVTLTCRSSTGAVTTSNYANWVQQKPDQAPTTLIYGTNNKHPWPPARFSGSLIGGKAALTVSGAQPEDEAIYFCALWYSNHWVFGGGTKLTVL
>Cabiralizumab VH (threshold 0.89)
QVQLVQSGPEVKKPGASVKVPCKASGYTFTDNYMIWVRQAHGKSLEWIGDINPYNGGTTFAQKFQGRGTLTVDKSISTAYMELRSLTSEDTAVYYCARESPYFSNLYVMDYWGQGTSVTVSS
>Cabiralizumab VL (threshold 0.78)
EIVLTQSPATLSVSLGQRATLSCKASQSVDYDGDNYLAWYQQKPGQPPRLLIYAASNRASGIPARFSGSGSGTDFTLNIHRLEEEDAATYYCHLSNEDLSTFGGGTKLEIK
>Camrelizumab VH (threshold 0.88)
QVQLVESGGGVVKPGGSLRLSCAASGFTFSSYMMSWVRQTPGKGLEWVSTISGGGANTYYADSVKGRFTISRDNAKNTLYLQMSSLRGEDTALYYCARQLYYFDYWGQGTLLTVSS
>Camrelizumab VL (threshold 0.8859999999999999)
DIQMTQSPASVSASLGDRVTITCLASQTIGTWLTWYQQKPGKAPQLLIYTATSLQTGVPSRFSGSGSGTDFTFTISSLQPEDFVTYYCQQVYSIPWTFGQGTKLEIK
>Cantuzumab VH (threshold 0.29)
QIQLVQSGYELKKPGETVKVSCKASDYTFTYYGMNWVRQAPGQGLKWMGWIDTTTGEPTYAQGFQGRFVFSLETSASTAYLQIKNLKNEDTATYFCARRGPYNWYFDVWGAGTTVTVSS
>Cantuzumab VL (threshold 0.182)
DIVMTQAAPSVPVTPGERVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVAVYYCLQHLEYPFTFGQGTKLELK
>Cergutuzumab VH (threshold 0.98)
QVQLVQSGAEAKKPGASVKVSCCASGYTFTEFGMNWVRQAPGQGLKWMGWINTKTGEATYVEEFQGRVAMTMDTSLSTVYMEIRNLKAEDMATYFCARWDFAYYVEAMDYWGQGTTVTVSS
>Cergutuzumab VL (threshold 0.887)
DIQMTQSQQFVSASVGDRVSVTCRASAAVGTYVAWDQQKPGQAPKALMYSASYLKRGVPSRFTGSGSGTDFTLTISNGQPEDLATYFCHQYYTYPLFTFGQGTKLEIK
>Certolizumab VH (threshold 0.855)
EVQRVESGGRLKKPGETLRGSCKASGYVFTDYGMNWVRQAPGKGLKWVSVINTYIGEPIYADSVKGRFAISRETSASTAYLQINNLKAEDTAVYFCARGYRSYAMDYWGQGTLVTVSS
>Certolizumab VL (threshold 0.862)
DIQMTQSQTSMSASVGDRVSVTCRASQNVGTNVAWYQQKPGQAPKALIYSASFLQSGVPYRFTGSGSGTDFTLTISNLQPEDLATYFCQQYNIYPLTFGQGTKLELK
>Citatuzumab VH (threshold 0.455)
QIQLVQSGSELKKPGATVKVSCKASGYTFTNYGMNWVRQAPGKALKWMGWINTYTGESTYAQGFKGRFVFSLEPSVSAAYLQINNLNAEDTATCFCARFAIKGDYWGQGTTLTVSS
>Citatuzumab VL (threshold 0.787)
AIQMTQVASSNSATVGDRATITCRATKSLLHSNGITYLYWYLQKPGKAPQLLIYQMSNLQSGVPSRFSSSGSGTDFTLRISRLQPEDFATYYCAQNLEIPRTFGQGTKLEMK
>Clivatuzumab VH (threshold 0.515)
EVQLQQSGPELKKPGASVKMSCKASGYTFPSYVLHWVRQAPGQGLEWMGYINPYNDGTQYAEKFQGKATLTSDKSISTAYMELSSLTSEDSAVYYCARGFGGSYGFAYWGQGTLVTVSA
>Clivatuzumab VL (threshold 0.82)
AIQLTQSPSIMSASVGDRVTMTCRASSSVSSSYLYWYQQKPGKAPKLLIYSTSNLQSGVPARFSGSGSGTSFSLTISSMQPEDAASYFCHQWNRYPYTFGQGTKLEIK
>Codrituzumab VH (threshold 0.965)
QVQLVQSGAEVKRPGASVTVSCKASGYTFTDYEMHWVRQAPVHGLEWIGALDPKTGDTAYSQKFQGRVILTADTSISTAYMELRSLTSEDTAVYYCTRFYSYTYWGQGTTVTVSS
>Codrituzumab VL (threshold 0.738)
DVVMTQTPLSLPVTLGQPASISCRSSQSLVHSNRNTYLHWYLQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQNTHVPPTFGQGTKLEIK
>Cofetuzumab VH (threshold 0.795)
QVQLIQSGPEVKRPGVSVKVSCKGSGYTFTDYAVHWVRQAHAQSLEWMGVISTYNDYTYNAQDFQGRATNTVDNSSSTDYMELARLTSEDSAINYCARGNSYFYALDYWGQGTLVTVSS
>Cofetuzumab VL (threshold 0.76)
EIVLTHSPATLPVSLGLRATLSCRASESVDSYGKSFLAWYQQKPGQPPRLLIYRASNRETGVPARFSGSGSRTDFTLTINRLEADDFATYYCQQSNEDPWTFGGGTKLEIK
>Concizumab VH (threshold 0.445)
QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFADSVQGRFTISRDNAKNTLYLQMSSLRVEDTAMYYCARLGGYDEGDAMDSWGQGTSVTVSS
>Concizumab VL (threshold 0.8740000000000001)
DVVMTQTPLTLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQRPGESPQLLIYLVSIRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGQGTKLEIK
>Crenezumab VH (threshold 0.865)
QVELVESGGGVVQPGGSLRLSCAASGFTFSSYGMSWVRQTPGKGLELVSSINSNGGSTYYADSVKGRFTISRDNAKNTLYLQMSSLRVEDTAVYYCASGDYWGQGTTLTVSS
>Crenezumab VL (threshold 0.826)
DIVMTQSPLSLPVTLGQPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKLEIK
>Crizanlizumab VH (threshold 0.86)
QVQLVQSGPEVNKPGALVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWIYPGDGSIKYAEKFQGRLTLTADKSSSTAYMELSSLTSENSAVYFCARRGEYGNYEGAMDYWGQGTSVTVSS
>Crizanlizumab VL (threshold 0.875)
DIQMTQSPSSLSASVGDRATITCQASQSVDYDGHSYLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLNIHSLQPEDFATYYCQQSDENPLTFGGGTKLEIK
>Dacetuzumab VH (threshold 0.81)
EVQGVESGGDLVKPGGSVRISCKASGYSFTGYYIHWVRQAHGKSLEWISRVIPNAGGTSYAQSVKGRFILSRDKSSNTLYMEMRSLTVEDSAVYYCAREGIYWWGQGTTVTVSS
>Dacetuzumab VL (threshold 0.759)
AIQMTQTPSSLSASVGDRVTITCRASQSLVHSNGNTFLHWYLQKPGKAPKLLIYTVSNLQSGVPSSFSGSGSGTDFTLTISRLQPEDLGTYFCSQTTHVPWTFGGGTKLEIK
>Daclizumab VH (threshold 0.65)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYAQKFQDKATLTWDKSISTAYMQLSSLTSDDSAVYYCARGGGVFDYWGQGTTLTVSS
>Daclizumab VL (threshold 0.903)
AIQLTQSPSIMSASVGDRVTMTCRASSSISYLHWYQQKPGTAPKRLIYTTSNLQSGVPARFSGSGSGTEFSLTISSLQPEDFATYYCHQRSTYPLTFGQGTKLEVK
>Dalotuzumab VH (threshold 0.99)
QVQLQQWGPGLVKPSETLSLTCSVYGYSITGGYLWNWIRQHPGEGLEWIGYISYDGTNNYKPSLKDRGSISIDTSKNQFSLKLTSVTTADTAVYYCARYGRVFFDYWGQGTTLTVSS
>Dalotuzumab VL (threshold 0.75)
DIVMTQSPLSLPVSLGQPASISCRSSQSIVHSNGNTYLQWYLQRPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKLEIK
>Dapirolizumab VH (threshold 0.715)
QVQLKESGGGLVQSGGTLRLTCTVSGFSSTNYHVHWVRQPPGKGLEWVSVIWGDGDTSYADVLKSRLSISNDTSKSSVFLKMNSLQTEDTAVYYCARQLTHYYVLAAWGQGASVTVSS
>Dapirolizumab VL (threshold 0.882)
DIQMTQTTSSMSASLGDRVTITCRASEDLYYNLAWYQRKPGRAPKLLIYDTYRLADGVPSRFSGSGSGADFTLTISSLQPEDVASYYCQQYYKFPFTFGQGTKLEIK
>Demcizumab VH (threshold 0.685)
QVQLVQSGPELKKTGASVKISCKASGYSFTAYYIHWVRQAHGKSLEWIGYISSYNGATNYAQKFQGKLTFTVDTSISTAYMELSSLTSEDSAVYYCARDYDYDVGMDYWGQGTSVTVSS
>Demcizumab VL (threshold 0.58)
DIVLTQSPDSLAVSLGDRATISCRSSESVDNYGISFMAWFQQKPGQPPKLLIYAASTRGSGVPARFSGSGSGTDFTLNIHPLQAEDAATYYCQQSKEVPWTFGGGTKLEIK
>Denintuzumab VH (threshold 0.83)
QLQLQQSGPGLVQPMETLSLTCAVSGFSLSTSGMGWGWIRQFSGKGLEWIAHIWWDDDKRYNPALKSRVTISADTSSNQFSLKIASVTAADTATYYCARMELWSYYFDYWGQGTTLTVSS
>Denintuzumab VL (threshold 0.835)
EIVLTQSPAIMSLSPGERVTLSCSASSSVSYMAWYQQKPGQAPRRLIYDTSKRASGVPARFSGSGSGTEFSLTISSLEPEDVATYYCFQGSVYPFTFGSGTKLEIK
>Dezamizumab VH (threshold 0.845)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTTYNMHWVRQAPGQGLEWMGYIYPGDGNANYAQQFQGRATLTADKSSSTAYMQLSSLTSEDSAVYYCARGDFDYDGGYYFDSWGQGTTLTVSS
>Dezamizumab VL (threshold 0.5670000000000001)
DIQMTQSPSSLSASVGERVTITCRASENIYSYLNWYQQKQGKAPQLLVHNAKTLQEGVPSRFSGSGSGTQFSLTINSLQPEDFGSYYCQHHYGAPLTFGQGTRLELK
>Domagrozumab VH (threshold 0.97)
QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYADSVKGRFTISRDNAKNTLYLQMSSLRVEDTAVYYCAKQDYAMNYWGQGTLVTVSS
>Domagrozumab VL (threshold 0.7040000000000001)
DIQMTQSPSFMSTSVGDRVSITCRASQDVSTAVNWYQQKPGQAPKLLIYSASYLYTGVPSRFTGSGSGTDFTFTISSVQAEDLATYYCQQHYSTPWTFGGGTKLEIK
>Duligotuzumab VH (threshold 0.94)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSGDWIHWVRQTPGKGLEWVSEISAAGGYTDYADSVKGRFTISRDNAKNNLYLQMSSLKVEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
>Duligotuzumab VL (threshold 0.988)
DIQMTQSQSFMSASVGDRVSVTCRASQNIATDLYWYQQKPGKAPKALIYSASFLQSGVPSRFTGSGSGTDFTLTISNLQPEDLATYFCQQSEPEPYTFGGGTKLEIK
>Eculizumab VH (threshold 0.975)
QVQLVQSGAEVMKPGASVKVSCKATGYTFSNYWIQWVRQAPGHGLEWMGWILPGSGSTEYAENFQDRATITADTSINTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGAGTTVTVSS
>Eculizumab VL (threshold 0.893)
DIQMTQSPSSLSASVGDRVTITCRASENIYGALNWYQRKPGKAPQLLIYGATNLQDGVSSRFSGSGSGTQFSLTISSLHPDDVATYYCQNVLNTPLTFGQGTKLELK
>Efalizumab VH (threshold 0.76)
QVQLQASGGGLVRPGWSVRLSCKASGYSFTGHWMNWVRQAPGQGLEWVSMIHPSDSETRYADSGKDRFTLSRDKSSSTLYMQMSSPTHEDSAVYYCARGIYFYGTTYFDYWGQGTLLTVSS
>Efalizumab VL (threshold 0.494)
DVQITQSPSYLAASPGERITINCRASKTISKYLNWYQEKPGKANKLLIYSGSTLQSGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGAGTKLELK
>Elotuzumab VH (threshold 0.375)
QVQLVESGGGVVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWISEINPDSSTINYADSLKDKFIISRDNAKNTLYLQMSKVRVEDTALYYCARPDGNYWYFDVWGAGTTVTVSS
>Elotuzumab VL (threshold 0.8059999999999999)
DIQMTQSHSFLSTSVGDRVSITCRASQDVGIAVAWYQQKPGQAPKLLIYWASTLHTGVPSRFTGSGSGTDFTLTISNLQPEDLATYFCQQYSSYPYTFGGGTKLEIK
>Emactuzumab VH (threshold 0.995)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTLTVDTSISTAYMELSSLTSEDTAVYYCARDQRLYFDVWGTGTTVTVSS
>Emactuzumab VL (threshold 0.966)
DIQMIQSPSSVSASVGERVTISCRASEDVNTYVSWYQQKPEQAPQLLIYAASNLQTGVPSRFTGSGSATDFTLTISSLQPEDFATYHCQQSFSYPTFGGGTKLEIK
>Emibetuzumab VH (threshold 0.945)
QVQLVQSGAEVKKPGASVKISCKASGYTFTDYYMHWVRQSHGKSLEWMGRVNPNRRGTTYAQKFQGAVTLTADKSISTAYMELSSLTSEDSAVYYCARANWLDYWGQGTTVTVSS
>Emibetuzumab VL (threshold 0.898)
DNQLTQSPSTLSASVGDRVTMTCRVSSSVSSIYLAWYQQKSGAAPKLLIYSTSNLQSGVPARFSGSGSGTEFSLTISSVQPEDAATYYCQVYSGYPLTFGQGTKLEIK
>Emicizumab VH (threshold 0.865)
QVQLVQSGAEVKKPGASVKIPCKASGYTFTDNNMDWVRQAPGKSLEWIGDINTRSGGSIYAEEFQDKVTLTVDKSISTAYMELRSLTSEDTAVYHCARRKSYGYYLDEWGEGTTVTVSS
>Emicizumab VL (threshold 0.872)
DIQMNQSPSSLSASLGDRITITCRASRNIERQLAWYQQKPGQAPKLLIYQASRKESGVPSRFTGSRYGTDFTLTISNVQPEDLATYFCQQYSDPPLTFGQGTKLELK
>Enavatuzumab VH (threshold 0.71)
EVQVVESGGGLVQPGGSLRLSCVASGFTFSSYWMSWVRQAPGKGLEWVSTIRLKSDNYATHYAESVKGKFTISRDDSKNRLYLQMNSLRAEDTGVYYCTTYYADAMDYWGQGTLVTVSS
>Enavatuzumab VL (threshold 0.813)
DIQLTQSPSSLSASVGDRVTISCRASQSVSTSSYSYLNWYQQKPGKAPKLLIKYASNLQSGVPARFSGSGSGTDFTLNIHNLQPEDTATYYCQHSWEIPYTFGGGTKLEIK
>Enoblituzumab VH (threshold 0.885)
QVQLVESGGGVVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADSVKGRFTISRDNPKNTLFLQMTSLRAEDTAVYYCGRGRENIYYGSRLDYWGQGTSVTVSS
>Enoblituzumab VL (threshold 0.88)
DIQMTQSQSFMSTSVGDRVSVTCRASQNVDTNVAWYQQKPGQAPKALIYSASYLYSGVPSRFTGSGSGTDFTLTISNLQPDDLATYFCQQYNNYPFTFGQGTKLEIK
>Enokizumab VH (threshold 0.84)
QVQLIQSGAEVNKPGASVKVSCKATGYTFSYYWIEWVRQAPGHGLEWIGEILPGSGTTNPAQKFFGRVTFTWDTSINTAYMGLSSLTSEDTAVYYCARADYYGSDYVKFDYWGQGTTLTVSS
>Enokizumab VL (threshold 0.9359999999999999)
DIQMTQSQIFVSASVGDRVTVTCRASQHVITHVTWYQQKPGQAPKALIYGTSYSQSGVPNRFTGSGSGTDFTLTISNLQPEDFATYFCQQFYEYPLTFGQGTKLELK
>Epratuzumab VH (threshold 0.64)
QVQLQQSGAELKRPGTSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWMGYINPRNDYTEYAQNFQDKATLTWDTSISTAYMELSSLTSDDSAFYYCARRDITTFYWGQGTTLTVSS
>Epratuzumab VL (threshold 0.66)
NIQMTQSPSSLAASVGERVTMSCRSSQSVLYSANHKNYLAWYQQKPGKATKLLIYWASTLQSGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCHQYLSSWTFGGGTKLEIK
>Etaracizumab VH (threshold 0.94)
QVQRVESGGGLVKPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLEWVSKVSSGGGSTYYLDAVQGRFTISRDNAKNTLYLQMSSLRVEDTAVYYCARHLHGSFASWGQGTLVTVSS
>Etaracizumab VL (threshold 0.95)
EIVLTQSTATLSVSPGDRASLSCQASQSISNFLAWYHQKSGQAPRLLIRYRSTRASGIPARFSGSGSGTDFTLTINSVETEDFAVYFCQQSGSWPLTFGGGTKLELK
>Farletuzumab VH (threshold 0.79)
QVQLVESGGDLVKPGGSLRLSCAASGFTFSGYGLSWVRQAPGKGLEWVSMISSGGSYTYYADSVKGRFAISRDNAKNTLYLQMSSLKVEDTAMYYCARHGDDPAWFAYWGQGTPVTVSS
>Farletuzumab VL (threshold 0.789)
EIQLTQSPSLMAASVGERVTITCLVSSSISSNNLHWYQQKSEKAPKPWIYGTSNLQSGVPVRFSGSGSGTSFSLTISSLQPEDAATYYCQQWSSYPYMYTFGQGTKLEIK
>Fibatuzumab VH (threshold 0.97)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTGYWINWVRQAPGQGLEWMGDIYPGSGNTNYAEKFQGRVTMTEDTSISTAYMDLSSLTSDDSAVYYCARGGYYEDFDSWGQGTTLTVSS
>Fibatuzumab VL (threshold 0.993)
DIPMTQSPSSLSASLGGRVTLTCRASQGIISYLAWLQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK
>Ficlatuzumab VH (threshold 0.73)
QVQLVQPGTEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWMGEINPTNGHTNYAQKFQGKATLTVDKSISTAYMALSSLTSEDSAVYYCARNYVGSIFDYWGQGTTLTVSS
>Ficlatuzumab VL (threshold 0.51)
NIVMTQSPDSMAMSLGERATLNCKSSENVVSYVSWYQQKTEQSPKLVIYGASNRESGVPDRFTGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGGGTKLEIK
>Flotetuzumab VH (threshold 0.705)
EVQLIQSGPEVKKPGASVKISCKASGYTFTDYYMKWVRQAHGKSLEWMGDIIPSNGATFYAQKFQGKATLTVDKSISTAYMELRSLRSEDSAVYYCARSHLLRASWFAYWGQGTLVTVSA
>Flotetuzumab VL (threshold 0.795)
DFVMTQSPDSLAVSLGERATMNCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK
>Fontolizumab VH (threshold 0.405)
QVQLKQPGAELKRPGSSVKLSCKASGYTFTSSWINWVKQAPIQGLEWMGRIDPSDGEVHYAQDFQDKATLTVDKSISTAYMQLSSLTSEDSAVYYCARGFLPWFADWGQGTLVTVSA
>Fontolizumab VL (threshold 0.932)
AIQMTQSPSSMSASIGERVTLSCRASENVDTYVNWYQQKPEKAPKLLIYGASNLYTGVPSRFTGSGSATDFTLTISSLQPEDLATYHCGQSYNYPFTFGQGTKLEVK
>Fremanezumab VH (threshold 0.875)
EVKLVESGGGLVQPGGSMRLSCVASGFTFSNYWISWVRQAPGKGLEWVSRIRSESDASATHYAEAVKGRFTISRDDSKSIVYLQMNSLRAEDTGVYYCLAYFDYGLAIQNYWGQGTLVTVSS
>Fremanezumab VL (threshold 0.98)
EIVMTQSPGTLSVSPGERDSLICRASKRVTTYVSWYQQKPGQSPRLLIYGASNRALGIPARFTGSGSATYFTLTISSVQPEDFAGYHCSQSYNYPYTFGQGTKLEIK
>Galcanezumab VH (threshold 0.945)
QVQLVQSGAEVKRPGTSVKVSCKASGYTFTNYWMQWARQAPGHGLEWMGIIYEGTGKTVYIQKFQDKVTITADKSTSTAYMAFSSLRSEDAAIYYCARLSDYVSGFGYWGQGTLLTVSS
>Galcanezumab VL (threshold 0.741)
DIQMTQTTSSLSASVGDRVTISCQASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGDALPPTFGGGTRLEIK
>Gatipotuzumab VH (threshold 0.74)
QVQLLESGGGLVQPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVSEIRLKSNNYTTHYAESVKGRFTISRDNAKNSVYLQMNNLRAEDTGVYYCTRHYYFDYWGQGTLLTVSS
>Gatipotuzumab VL (threshold 0.608)
DIVMTQSPFSLPVTLGQPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNRASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGGGTKLEIK
>Gemtuzumab VH (threshold 0.625)
EVQLIQSGPEGKKPGASVKISCKASGYTFTDSNIHWVRQSPGKSLEWMGYIYPYNGGTDYAQKFQNKVTLTVDNPISTAYMELRSLTSEDSAFYYCANGNPWLAYWGQGTLVTVSA
>Gemtuzumab VL (threshold 0.922)
DIQLTQSPSTLSASVGDRATITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNLQSGVPSRFSGSGSGTDFSLNISSLQPDDFATYFCQQTKEVPWSFGGGTKVEVK
>Gevokizumab VH (threshold 0.4)
QVTLKESGPGILKPSETLSLTCSFSGFSLSTSGMGWGWIRQPSGKGLEWIAHIWWDGDESYNPSLKSQLTISVDTSRNQVFLKITSVDTADTATYYCARNRYDPPWFVDWGQGTLVTVSA
>Gevokizumab VL (threshold 0.524)
AIQMTQTTSSLSASLGDRVTISCRASQDISNYLSWYQQKPDKAPKLLIYYTSKLHSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCLQGKMLPWTFGQGTKLEIK
>Ibalizumab VH (threshold 0.25)
EVQLQQSGPELRKPGASVKMSCKASGYTFTSYVIHWVKQAPGQGLDWIGYINPYNDGTDYDEKFQGKATLTSDKSISTAYMELSSLTSEDSAVYYCAREKDNYATGAWFAYWGQGTLVTVSA
>Ibalizumab VL (threshold 0.755)
DIVMTQSPDSLAVSLGERATMSCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLKAEDLAVYYCQQYYSYRTFGGGTKLEIK
>Idarucizumab VH (threshold 0.765)
QVQLQQWGPGLVAPSEALSITCTVSGFSLTSYIWDWVRQSPGKGLEWIGEIWAGGSTGYNSSLRSRVSISVDNSKSQVSLKMNSVTTADTAMYYCASAAYYSYYNYDGFAYWGQGTLVTVSA
>Idarucizumab VL (threshold 0.9)
DVVMTQSPLSLSVTPGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKLEIK
>Ifabotuzumab VH (threshold 0.97)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTGYWINWVRQAPGQGLEWMGDIYPGSGNTNYAEKFQGRVTMTEDTSISTAYMDLSSLTSDDSAVYYCARGGYYEDFDSWGQGTTLTVSS
>Ifabotuzumab VL (threshold 0.993)
DIPMTQSPSSLSASLGGRVTLTCRASQGIISYLAWLQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK
>Iladatuzumab VH (threshold 0.69)
QVQLQQPGAENMKPGASLRISCAATGYTFSSYWIEWVKQAPGHGLEWVSEILPGGGDTNYAEIVKGEATFTRDTSKNTAYMQMSSLRAEDSAVYYCARRVPIRLDYWGQGTLVTVSA
>Iladatuzumab VL (threshold 0.8590000000000001)
DIQMTQSPSTLSASVGDRATITCRASQSVDYEGDSFLNWFQQKPGKAPKLLIYAASNLQSGVPARFSGSGSGTDFTLNIHSLQPEDFATYYCQQSNEDPLTFGAGTKLEIK
>Imgatuzumab VH (threshold 0.995)
QVQLGQSGAEVKKPGASVKVSCKASGYTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTLTADKSTSTAYMELSSLTYEDTAVYYCARLSPGGYYVMDAWGQGTSVTVSS
>Imgatuzumab VL (threshold 0.73)
DIKMHQSPPSLYPSLGARVTITCRASQGINNYLNWYQQKPGEGPKRLIYNTNNLQTGVPSRFSGSGSGQDFSLTISNLQPEDMGIYYCLQHNSFPTFGQGTRLELK
>Inebilizumab VH (threshold 0.895)
EVQLQESGGCLVKPGWSLRISCVASGYAFSSSWMNWVRQAPGKGLEWVSVIYPGDGDTNYAVSAKGRFTLSRDKSSSTAYMQMSSLRVEDTAVYFCARSGFITTVRDFDYWGQGTLLTVSS
>Inebilizumab VL (threshold 0.655)
EIVLTQSPAFQAVTLKQKATITCRASESVDTFGISFMNWFQQKPDQPPKLLIHEASQSGSGVPARFSGSGSGTDFTLNIHPLEEDDAAMYFCQQSKEVPFTFGSGTKLEIK
>Inotuzumab VH (threshold 0.91)
QVQLVQSGTVVKRPGASVKVSCKASGYRFTNYWIHWVGQAPGQGLEWIGGINPGNNYATYRRKFQGRVKLTAVTSTSTAYMELSSLTNEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSA
>Inotuzumab VL (threshold 0.6970000000000001)
DVQVTQTPSSLSASFGDRVSISCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNLQSGVPSRFSGSGSGTDFTLTISTLQPEDFATYYCLQGTHQPYTFGSGTKLEIK
>Itolizumab VH (threshold 0.07)
QVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQTPEKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTTLTVSS
>Itolizumab VL (threshold 0.256)
DIKMTQSPSSTYASLGARVTITCKASRDIRSYLTWYQQKPWKAPKTLIYYATSLADGVPSRFSGSGSGQDFSLTISSLQSDDTATYYCLQHGESPFTLGSGTKLEIK
>Ixekizumab VH (threshold 0.9)
QVQLIQSGPELKKPGASVKVSCKASGYSFTDYHIHWVRQAPGKGLEWMGVINPMYGTTDYAQRFQGRATLTVDQSISTAYMELNSLTSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSA
>Ixekizumab VL (threshold 0.8640000000000001)
DIVLTQSTLSLPVTLGQPASISCRSSRSLVHSRGNTYLHWYLQRPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK
>Labetuzumab VH (threshold 0.605)
EVQLQESGGGLVQPGGSLRLSCAASGFDFSTYWMSWVRQAPGKGLEWVSEIHPDSSTINYADSLKDKFIISRDNAKNTLYLQMSSVRVEDTALYYCATLYFGFPWFAYWGQGTPVTVSA
>Labetuzumab VL (threshold 0.8640000000000001)
DIQMTQSPSFLSTSVGDRVSITCRASQDVGTSVAWYQQKPGQAPKLLIYWTSTLHTGVPSRFTGSGSGTDFTLTISNLQPEDLATYFCQQYSLYRSFGGGTKLEIK
>Lacnotuzumab VH (threshold 0.73)
QVQLQESGPGLVKPSATLSLTCTVDDYSITSDYAWNWIRQAPGNGLEWIGYISYSGSTSYNPSLKSRISITVDTSKNQFSLQLNSVTTADTAVYYCARFDYAHAMDYWGQGTSVTVSS
>Lacnotuzumab VL (threshold 0.59)
DILLTQSPDIQSVSPKEKVSFSCQASQSIGTSIHWYQQKTDQSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDAADYYCQQINSWPTTFGGGTKLEIK
>Ladiratuzumab VH (threshold 0.995)
QVQLIQSGAEVKKPGASVKVSCTASGLNIEDYYMHWVRQAPAQRLEWAGAIDPENGDTEYGQKFQGRVTMTADTSINTAYMELSSLTSEDTAVYYCNVHNAHYGTWFAYWGQGTLVTVSS
>Ladiratuzumab VL (threshold 0.866)
DVLMTQSPPSLPVTLGQQASISCRSSQSLLHSSGNTYLEWFLQRPGQSPQPLIYKISTRFSGVPDRFSGSGSGTDFTLKISSVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK
>Lambrolizumab VH (threshold 0.88)
QVQLVQSGVEVKKPGVSVKLSCKASGYTFTNYYMYWVRQAPGQDLEWMGGINPSNGGTNFAEKFQNRATPTVDSSISTAYMELKSLQFEDSAVYFCARRDYRFDMGFDYWGQGTTLTVSS
>Lambrolizumab VL (threshold 0.87)
EIVLTQSPATLSVSPGQRATLSCRASKGVSTSGYSYLAWYQQKPGQPPRLLIYLASYRETGVPARFSGSGSGTDFTLNIHSLEEEDFATYYCQHSRDLPLTFGGGTKLEIK
>Lampalizumab VH (threshold 0.53)
QIQLVQSGSELKKPGATVKVSCKASGYTFTNYGMNWVRQAPGKGLKWMGWINTYTGETTYAQDFTGRFVFSLDTSVSTAYLQINNLKAEDMAVYSCEREGGVNNWGQGTMVTVSA
>Lampalizumab VL (threshold 0.764)
ATQVTQSPSSLSMAIGDRVTIRCQTSTDIDDDLNWYQQKPGEAPKLLISGGNTLQPGVPSRFSSSGSGTDFTFTIENMQSEDVATYYCLQSDSLPYTFGQGTKLEIK
>Landogrozumab VH (threshold 0.985)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYPMSWVRQAPGKGLEWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRVEDTAVYYCARLPDYWGQGTLVTVSS
>Landogrozumab VL (threshold 0.95)
ENVLTQSPAILSLSPGEKATLSCRASSSVSSSYLAWYQQKSGQAPRLLIYSTSNRVAGVPARFSGSGSGTEFSLTISSVEAEDFAVYYCQHHSGYHFTFGQGTKLEIK
>Lebrikizumab VH (threshold 0.7)
QITLRESGPTLVAPTQTLTLTCTFSGFSLTAYSVGWARQPPGKALEWLGLIWGDGKIVYNSALKSRLSISKDTSKSQVFLTMNDMDTVDTARYYCARDGYYPYAMDNWGQGSSVTVSS
>Lebrikizumab VL (threshold 0.61)
DIVMTQSPDSLAVSLGERATISCRSSKSVDSYGNSFLHWYQQKPGQPPKLLIYLASNRESGVPDRFSGSGSRTDFTLTIDPLQADDAATYYCQQNNEDPRTFGGGTKLEIK
>Lifastuzumab VH (threshold 0.945)
QVQLVESGGGVVQPGKSLRLSCAASGFSFSDFAMSWVRQSPGMGLEWVATIGRVAFHTYYADSMKGRFIISRDNAKNTLYLQMDSLRVEETAVYYCARHRGFDVGHFDFWGPGTLVTVSS
>Lifastuzumab VL (threshold 0.725)
AIQMTQTPSTLPASVGDRAAISCRSSETLVHSSGNTYLEWYLQKPGKAPKLLIYRVSNLQSGVPSRFSGSGSGTDFTLTISRLQPEDFGTYYCFQGSFNPLTFGAGTKLEMK
>Ligelizumab VH (threshold 0.79)
QVQLVQPGAEVKRPGSSVKLSCKASGYTFTWYWLEWVRQAPIHGLEWMGEIDPGTFTTNYAEKFQAKVTFTVDKSTSTAYMELSSLTSEDSAVYYCARFSHFSGSNYDYFDYWGQGTTLTVSS
>Ligelizumab VL (threshold 0.93)
EILLTQSPAILSVSPGERASFSCRASQSIGTNLAWYQQKTGQSPRLLIYYASTRATGIPSRFSGSGSGTDFTLSINSVESEDFADYYCQQSWSWPTTFGGGTKVEIK
>Lintuzumab VH (threshold 0.61)
QVQLVQSGAELKKPGASVKVSCKASGYTFTDYNMHWVRQSHGKSLEWIGYIYPYNGGTGYAQKFQSKVTLTVDNSISTAYMELRSLTSEDSAVYYCARGRPAMDYWGQGTSVTVSS
>Lintuzumab VL (threshold 0.8859999999999999)
DIQLTQSPSTLSASVGDRATITCRASESVDNYGISFLAWFQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFSLNIHSLQPDDFATYFCQQSKEVPWTFGQGTKLEIK
>Lorvotuzumab VH (threshold 0.985)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVSGISSGSFTIYYADSVKGRFTISRDNAKNTLFLQMNSLRVEDTAVYYCARMRKGYAMDYWGQGTLVTVSS
>Lorvotuzumab VL (threshold 0.924)
DVVMTQTPLSLPVTLGQPASISCRSSQIIIHSDGNTYLYWFQQRPGQSPQRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKLEIK
>Lumretuzumab VH (threshold 0.96)
QVQLAQSGAEVKKPGASVKLSCKTSGFTFSSSYISWLRQAPGQGLEWMAWIYAGTGSPSYAQKLQGRCQLTVDTSISTAYMEFSSLRTEDSAIYYCARHRDYYSNSLTYWGQGTTLTVSS
>Lumretuzumab VL (threshold 0.975)
DIVMTQSPDSLTVSLGERATMHCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRASGVPHRFSGSGSGTDFTLTISSLQPEDVAVYYCQSDYSYPYTFGGGTKLEIK
>Lutikizumab VH (threshold 0.885)
QVKLAESGGGVVKPGGSLGLSCAASGFTFSRYDMSWVRQAPGKGLEGVSYISHGGAGTYYADSVKGRFTISRDNAKNNLYLQMNHLRVEDTAMYYCARGGVTKGYFDVWGTGTPVTVSS
>Lutikizumab VL (threshold 0.637)
DIQMTQSPSSLSASVGERVTITCRASGNIHNYLTWYQQTQGKAPQLLIYNAKTLQDGVPSRFSGSGSGTQFTLTINSLQPEDFGIYYCQHFWSIPYTFGQGTKLQIT
>Matuzumab VH (threshold 0.62)
QVQLVQSGAEVKKPGASVKLSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYAEKFQSKATLTVDKSMSTAYMQLSSLTSEDSAVYYCASRDYDYDGRYFDYWGAGTTVTVSS
>Matuzumab VL (threshold 0.821)
DIQLTQSPSILSASVGERVTMTCSASSSVTYLYWYQQKPGSAPRLLIYDTSNLQSGVPVRFSGSGSGTEFSLTISSLQPEDAATYYCQQWSSHIFTFGQGTKLEIK
>Mepolizumab VH (threshold 0.555)
QITLRESGPTLVAPTQTLTITCTFSGFSLTSYSVHWVRQPPGKALEWLGVIWASGGTRYNSALMSRLSISKDNSKSQVCLKMTSMDIVDPAMYYCARDPPSSLLRLDYWGQGTPVTVSS
>Mepolizumab VL (threshold 0.97)
DIVMTQSPDSLSVSLGERASINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGCGTKVEIK
>Milatuzumab VH (threshold 0.505)
QLQLVQSGSELKKPGATVKVSCKASGYTFTNYGVNWVRQAPGKGLQWMGWINPNTGEPTFDQGFAGRFAFSLETSVSTAYLQLTNLKNEDTATYFCSRSRGKNEAWFAYWGQGTLVTVSA
>Milatuzumab VL (threshold 0.8220000000000001)
DIVLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLDWYLQKPGQSPQLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGQGTKLEIK
>Mirikizumab VH (threshold 0.855)
QVQLVQSGPEVKKPGASVKVSCKASGYKFTRYVMHWVRQAPGQGLEWIGYINPYNDGTNYAEKFQGRATLTSDKSISTAYMELSSLTSEDSAVYYCARNWDTGLWGQGTLVTVSA
>Mirikizumab VL (threshold 0.889)
DIQMTQSPSSLSASVGGRVTITCRASDHILKFLTWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGTDFTLTITSLQPDDVATYYCQMYWSTPFTFGQGTKLEIK
>Mogamulizumab VH (threshold 0.76)
QVQLVESGGDLVKPGGSLSLSCAASGFTFSNYGMSWVRQAPGKGLEWVSTISSASTYSYYADSVKGRFTISRDNAKNTLYLQMSSLKVEDTAVYYCGRHSDGNFAFGYWGQGTTLTVSS
>Mogamulizumab VL (threshold 0.792)
DVLMTQSPLSLPVTLGQPASISCRSSRNIVHINGDTYLYWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKLEIK
>Monalizumab VH (threshold 0.995)
QVQLVQSGAEVKKPGSSAKASCKASGYTFTSYWFNWVRQAPIQGLEWMGRIDPYDSETMYAQKAQGWLTLTVDKSISTAYMELSSLTSEDTAVYYCARGGYDFDVGTLYWFFDVWGTGTTVTVSS
>Monalizumab VL (threshold 0.515)
DIQMTQSPASLSASVGERVTITCRASENIYSYLNWYQQKQGKAPQLLIYNAKTLQEGVPSRFSGSGSGTQFSLTINSLQPEDFGSYYCQHHYGTPRTFGGGTRLEIK
>Mosunetuzumab VH (threshold 0.67)
QVQLVQSGAEVNRPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWMAWIYPGDGNTKYAEKFKGKVTLTAEKSISTAYMQLSSLTSEDSAVYFCARDSYSNYYFDYWGQGTTLTVSS
>Mosunetuzumab VL (threshold 0.985)
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFTGDGSGTDFTLTISSLQAEDAAVYYCTQSFILRTFGQGTKLEIK
>Motavizumab VH (threshold 0.905)
QVTLRVSGPTLLKPTEALTLTCSFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKMANGDPADTATYYCARDMIFNFYFDVWGTGTTVTVSS
>Motavizumab VL (threshold 0.8490000000000001)
DIQMTQSPSIMSASVGERVTITCRASSRVGYMAWYQQKSGTAPKRLIYDTSKLQSGVPARFSGSGSGTSFTLTISSLQPEDAATYYCFQGSGYPFTFGQGTKLEIK
>Natalizumab VH (threshold 0.95)
QVQLVQSGAELKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWAGWIDPANGYTKYDPKFQGRVTITADTSINTAYLELSSLRSDDTAIYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
>Natalizumab VL (threshold 0.499)
AIQMTQSPSSLSASLGGRVTITCRTSQDINKYMAWYQHTPGKGPRLLIHYTSALQPGVPSRFSGSGSGRDFSFSISNLQPEDIATYYCLQYDNLWTFGQGTKLEIK
>Nemolizumab VH (threshold 0.93)
EVQLVQSGAEVKKPGASVKMSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYAPQFQDRVTLTSDKSISTAYMELSSLTSEDSAVYDCARDGYDDGPYTLETWGQGTLLTVSS
>Nemolizumab VL (threshold 0.645)
DIQMTKSPASLSASVGERVTITCQASEDIYSFVNWYQQKQGKAPQLLVYNAQTEQQGVPSRFSGSGSGTQFSLTISSLQPEDFGSYYCQHHYDSPLTFGAGTKLELK
>Nimotuzumab VH (threshold 0.775)
QVQLAQSGAEVKKPGASVKLSCKASGYTFTNYYIYWVRQAPGQGLEWMGGINPTSGGSNFAEKFQTKATLTVDKSSSTAYMELSSLTSEDSAFYYCTRQGLWFDSDGRGFDFWGQGTTLTVSS
>Nimotuzumab VL (threshold 0.6859999999999999)
AVQMTQTPSTLPASVGDRASITCRASQNIVHSNGNTYLDWYLQTPGQAPKLLIYKVSNLQSGVPSRFSGSGSGTDFTLTISRLQPEDLGTYYCFQYSHVPWTFGGGTKLQIT
>Obinutuzumab VH (threshold 0.83)
QVQLVQSGPEVKKPGASVKVSCKASGYAFSYSWINWVRQAPGQGLEWIGRIFPGDGDTDYAGKFQGKLTLTWDKSTSTAYMHLSSLTSVDSAVYFCARNVFDGYWLVYWGQGTLVTVSS
>Obinutuzumab VL (threshold 0.562)
DIVMTQAPFSLPVTLGQSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNRVSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK
>Ocaratuzumab VH (threshold 0.805)
EVQLVQSGAEVNRPGESVKMSCKASGRTFTSYNNGWVRQTPRQGLEWMGAIYPLTGDTSYNPSSQLHATLSVDKSISTAYLQWSSLTASDSAVYFCARSTYVGGDWQFDVWGTGTTVTVSS
>Ocaratuzumab VL (threshold 0.91)
EIVLSQSPAILSLSPGEKATASCRASSSVPYIAWYQQKPGQSPRPVIYATSARATGIPARFSGSGSGTEYSLTISRVEAEDFAVYYCQQWLSNPPTFGGGTKVEIK
>Ocrelizumab VH (threshold 0.78)
QVQLLQSGGGEVRPGMSLRMSCAASGYTFTSYNMHWVRQAPRQGLEWVSAIYPGNGDTSYAQSVKGRATLTVDKSKSTAYMQMSSLTVEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS
>Ocrelizumab VL (threshold 0.862)
AIQLSQSPSSLSASVGERVTMTCRASSSVSYLHWYQQKPGKAPKPLIYAPSNLQSGVPARFSGSGSGTSFSLTISRVQPEDFATYYCQQWSFNPPTFGQGTKLEIK
>Olendalizumab VH (threshold 0.895)
QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYSMDWVRQAHGQSLEWIGWIHLNTGYTNYAQKFQGRLTLNVDKSISTAYMELRSLTSEDSAVYYCARGFYDGYSPMDYWGQGTSVTVSS
>Olendalizumab VL (threshold 0.816)
DIQLTQSPSTLAASVGDRATITCRASESVDSYGNSFLAWYQQKPGKAPKLLIYRASNLQSGVPARFSGSGSRTDFTLTISSLQPDDVATYYCQQSNEDPYTFGGGTKLEIK
>Omalizumab VH (threshold 0.845)
EVQLLESGGGLVQPGGSLRLTCSVTGYSITSGYSWNWIRQAPGNKLEWMHSITYDGSTNYADSVKGRVSITRDTSKNQFFLKMNSVTAEDTAVYYCARGSHYFGHWHFAVWGTGTTVTVSS
>Omalizumab VL (threshold 0.8740000000000001)
DIQLTQSPSSLSASVGDRATITCRASQSVDYDGDSYLNWYQQKPGKAPKLLIYAASYLQSGVPSRFSGSGSGTDFTLNIHSLQPEDFATYYCQQSHEDPYTFGGGTKVEIK
>Onartuzumab VH (threshold 0.725)
QVQLMQSGGALVQPGWSLRMSCTASGYTFTSYWLHWVRQAPGQGLEWVSMIDPSNSDTRFAPSVKDAFTLNVDKSKNTAYMQLSSLTVEDSAVYYCATYRSYVTPLDYWGQGTTLTVSS
>Onartuzumab VL (threshold 0.73)
DIQMSQSPSSLAASVGERATMSCRSSQSLLYTSSQKNYLNWYQQKPGKAPKLLIYWASTLQSGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGGGTKLEIK
>Oportuzumab VH (threshold 0.455)
QIQLVQSGSELKKPGATVKVSCKASGYTFTNYGMNWVRQAPGKALKWMGWINTYTGESTYAQGFKGRFVFSLEPSVSAAYLQINNLNAEDTATCFCARFAIKGDYWGQGTTLTVSS
>Oportuzumab VL (threshold 0.787)
AIQMTQVASSNSATVGDRATITCRATKSLLHSNGITYLYWYLQKPGKAPQLLIYQMSNLQSGVPSRFSSSGSGTDFTLRISRLQPEDFATYYCAQNLEIPRTFGQGTKLEMK
>Otlertuzumab VH (threshold 0.815)
EVQLVQSGPEAKKPGESLKISCKGSGYSFTGYNIGWVRQMNGKSLEWMGNIDPYYGGTTYNRSFQGKVTLTVDKSISTAYMQWKSLTASDSAVYYCARSVGPFDSWGQGTTLTVSS
>Otlertuzumab VL (threshold 0.98)
EIVMTQSPATLSVSPGETVTLTCRASENVYSYLAWYQQKAGQAPRLLVYFAKTRATGVPARFSGSGSGTQFSLTINSLQPEDFASYYCQHHSDNPWTFGGGTKLEIK
>Ozanezumab VH (threshold 0.63)
QVQLQQSGTELKKPGASVKLSCKASGYTFTSYWMHWVRQAPGQGLEWMGNINPSNGGTNYAEKFQSKVTLTVDKSMSTAYMELSSLTSEDSAVYYCELMQGYWGQGTTLTVSS
>Ozanezumab VL (threshold 0.586)
DIVITQSELSLPVTSGEPASISCRSSKSLLYKDGKTYLDWYLQRPGQSPQLLIYLMSTRASGVPDRFSGSGSGTDFTLEISRVKAEDVGVYYCQQLVEYPLTFGQGTKLELK
>Palivizumab VH (threshold 0.885)
QVTLRVSGPTLVKPTQTLTLTCSFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSQLTISKDTSRNQVVLTITNVDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
>Palivizumab VL (threshold 0.8759999999999999)
DIQLTQTPSIMSASVGDRVTMTCRCQLSVGYWHWYQQKSSTAPKLLIYDTSKLQSGVPGRFSGSGSGNEFSLTISSMQPEDVATYYCFQGSGYPFTFGQGTKLEIK
>Parsatuzumab VH (threshold 0.815)
EVQLMQSGGCLVQPGGSLRISCVASGYTFTDYYMNWVAQAHGKSLEWISDINLDNSGTHYAQKEKGRATLTVDKSKSTAYMQLSSLTVEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTGSS
>Parsatuzumab VL (threshold 0.8190000000000001)
AVQMTQTPSSLPASVGDRASITCRTSQSLVHINAITYLNWYQQKPGKAPKLLIYRVSNLQSGVPSRFSGSGSGTDFTLTISRLQPEDLATYFCGQSTHVPLTFGQGTKLEMK
>Pateclizumab VH (threshold 0.69)
EVQLKESGGGLVKPGWSLRMSCAMSGYTFTSYVISWVGQAPGQGLEWISYNNPYNAGTNYAEKVKGLATLSSDKSMNTAYMEMSSLRAEDSAVYYCSRPTMLPWFAYWGQGTLVTVSA
>Pateclizumab VL (threshold 0.9620000000000001)
DIQITQSPSFMSASVGDRVSITCRASQAVSSALNWYQQKPGQAPKLLIYSASHLYTGVPSRFTGSGSGTDFTFTISSLQPEDLATYYCQESYSTPWTFGGGTKLEIK
>Pembrolizumab VH (threshold 0.88)
QVQLVQSGVEVKKPGVSVKLSCKASGYTFTNYYMYWVRQAPGQDLEWMGGINPSNGGTNFAEKFQNRATPTVDSSISTAYMELKSLQFEDSAVYFCARRDYRFDMGFDYWGQGTTLTVSS
>Pembrolizumab VL (threshold 0.87)
EIVLTQSPATLSVSPGQRATLSCRASKGVSTSGYSYLAWYQQKPGQPPRLLIYLASYRETGVPARFSGSGSGTDFTLNIHSLEEEDFATYYCQHSRDLPLTFGGGTKLEIK
>Perakizumab VH (threshold 0.955)
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVSIIKSGGSYSYYVDSVKGRFTISRDNAKNNLYLQMNSLRVEDTAMYYCARDGDYGSSYGAMDYWGQGTLVTVSS
>Perakizumab VL (threshold 0.568)
DIKMTQSPSSMYASLGERVTITCRASQDINSYLSWFQQKPGKAPKTLIVRANRLQDGVPSRFSGSGSGTDFSLTISSLQPEDRGIYYCLQYDAFPPYTFGQGTKLEIK
>Pertuzumab VH (threshold 0.875)
EVQLVESGGELVKPGGSLRIPCVASGYTFTDYTMDWVGQAHGKSLEWISDVNPNSGGSIYADRAKGGFTISRDKSKSTLYMEMRSLTAEDTAVYYCARNLGPSFYFDYWGQGTTVTVSS
>Pertuzumab VL (threshold 0.888)
DIQMTQSHSFMSASVGDRVSITCRASQDVSIGVAWYQQKPGQAPKLLIYSASYLYTGVPSRFTGSGSGTDFTFTISSLQPEDLATYYCQQYYIYPYTFGGGTKLEIK
>Pidilizumab VH (threshold 0.595)
QIQLVQSGYELKKPGESVKVSCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAQGFAGRFVFSLDTSVSTAYLQINNLKAEDTATYFCVRVGYDALDYWGQGTSVTVSS
>Pidilizumab VL (threshold 0.63)
AIQLTQSPSIMSASVGEMVTITCSARSSVSYMHWFQQKPGTAPKLWIYRTSNLQSGVPARFSGSGSGTSFCLTISRMQPEDAATYYCQQRSSFPLTFGQGTKLELK
>Pinatuzumab VH (threshold 0.86)
EVQLVESGGELIKPGASLRISCVASGYEFSRSWMNWVGQAPGKGLEWVSRIYPGDGDTNYSGSFKGRLTLSRDKSKKTAYMQMSSLRVEDTAVYFCARDGSSWDWYFDVWGTGTTVTVSS
>Pinatuzumab VL (threshold 0.741)
AVQMTQTPSTLPASVGDRASITCRASQSIVHSVGNTFLEWYLQKPGKAPKLLIYKVSNLQSGVPSRFSGSGSGTDFTLTISRLQPEDLGTYYCFQGSQFPYTFGGGTKLEIK
>Pogalizumab VH (threshold 0.825)
QLQLVQSGPEVKEPGASMKVSCKASGYTFTDSYMSGVRQSHGKSLEWMGDMYPDNGDSSYAQKFQESATLTVDRSISTAYMELDSLTSEDTAAHYCVLAPRWYFSVWGAGTTVTVSS
>Pogalizumab VL (threshold 0.674)
DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSNLRSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGHTLPPTFGQGTKLEIK
>Polatuzumab VH (threshold 0.69)
QVQLQQPGAENMKPGASLRISCAATGYTFSSYWIEWVKQAPGHGLEWVSEILPGGGDTNYAEIVKGEATFTRDTSKNTAYMQMSSLRAEDSAVYYCARRVPIRLDYWGQGTLVTVSA
>Polatuzumab VL (threshold 0.8590000000000001)
DIQMTQSPSTLSASVGDRATITCRASQSVDYEGDSFLNWFQQKPGKAPKLLIYAASNLQSGVPARFSGSGSGTDFTLNIHSLQPEDFATYYCQQSNEDPLTFGAGTKLEIK
>Prasinezumab VH (threshold 0.875)
QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYGMSWVRQTPGKGLEWVASISSGGGSTYYADNVKGRFTISRDNSKNTQYLQMDSLRVEDTAVYYCARGGAGIDYWGQGTLVTVSS
>Prasinezumab VL (threshold 0.645)
AIQMSQSPSSLAASVRDRVTMSCRSIQTLLYSSNQKNYLNWYQQKPGKAPKLLIYWASILKSGVPSRFTGSGSGTDFTLTISSLKPEDLATYYCQQYYSYPLTFGQGTKLELK
>Quilizumab VH (threshold 0.8)
QVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGINWVRQAPRKGPEWVAFISDLAYTIYYADSVTGRFTISRENAKNTLYLEMSSLRVEDTAVYYCARDNWDAMDYWGQGTLVTVSS
>Quilizumab VL (threshold 0.759)
AVQMTQTPLTLPASVGDRASISCRSSQSLVHNNANTYLHWYLQKPGKAPKLLIYKVSNLQSGVPSRFSGSGSGTDFTLTISRLQPDDFATYYCSQNTLVPWTFGGGTKLEIK
>Ralpancizumab VH (threshold 0.875)
QVQLVQSGAEVKKPGASVKLSCKASGYTFTSYYMHWVRQAPGQGLEWIGEIHPSGGRTNYAEKFQSRATMTVDKSISTAYMALSSLTSEDTAVYYCARERPLYASDLWGQGTSVTVSS
>Ralpancizumab VL (threshold 0.872)
DIQMTQSHSSMSASVGDRVSITCRASQDVHTAVNWYQQKPGQAPKLLIYHASYLYTGVPGRFTGSGSGTDFTFTISSLQAEDLATYYCQQRYSLWRTFGGGTKLEIK
>Ranibizumab VH (threshold 0.805)
QEQLVQSGGNLKKPGESLRISCAASGYDFTHYGMNWVRQAPGKGLKWVSWINTYTGEPTYAASGKRRFAFSRENSKDTAYLQINNLKNEDMAVYFCARYPYYYGTSHWYFDVWGHGTTVTVSS
>Ranibizumab VL (threshold 0.914)
DIQMTQSTSSLSASVGDRVTISCQASQDISNYLNWYQQKPGKAPKLLIYFTSSLHSGVPSRFSGSGSGTDFFLTISNLQPEDIATYYCQQYSTVPWTFGGGTKLEIK
>Ravulizumab VH (threshold 0.975)
QVQLVQSGAEVMKPGASVKVSCKATGHTFSNYWIQWVRQAPGQGLEWMGWILPGSGHTEYAENFQDRATFTADTSINTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGAGTTVTVSS
>Ravulizumab VL (threshold 0.893)
DIQMTQSPSSLSASVGDRVTITCRASENIYGALNWYQRKPGKAPQLLIYGATNLQDGVSSRFSGSGSGTQFSLTISSLHPDDVATYYCQNVLNTPLTFGQGTKLELK
>Refanezumab VH (threshold 0.88)
QVQLVQSGSEWKKPGASVKVSCKASGYTFTNYGMNWVGQAPGQGLEWMGWINTYTGEPTYAQGFTGRFVFSLETSVSTAYLQINNLKAEDTAVYFCARNPINYYGINYEGYVMDYWGQGTLVTVSS
>Refanezumab VL (threshold 1.0)
DIMMTQSPDSLAVSLGEGATIACKSNHSVLYSSNQKNYLAWYVQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEAK
>Reslizumab VH (threshold 0.76)
QVQLLESGGGLVQPGGTLRLTCTVSGLSLTSNSVNWIRQPPGKGLEWMSLIWSNGDTDYASAIKGRLVISRDTSKNSVFLKMNSLQAEDTAMYFCAREYYGYFDYWGQGNMVTVSS
>Reslizumab VL (threshold 0.7909999999999999)
DIVLTQSPSSMYSSVGDRVTITCLASEGISSYLAWFQQKPGKAPKTLISGANSLQTGVPSRFSGSGSATDFSLTISSLDPEDVGIYYCQQSYKFPNTFGGGTKLEVK
>Risankizumab VH (threshold 0.77)
QVQLVQSDAEVRKPGASVKISCKVSGYTFTDQTIHWMRQAPEQGLEWMGYIYPRDDSPKYAENFLGKVTLTADKSSSTAYMELNSLTSEDYAVYFCAIPDRSGYAWFIYWGQGTLVTVSA
>Risankizumab VL (threshold 0.6759999999999999)
DIQMTQSHSFMSTSVGDRVSITCRASRDVAIAVAWYQQKPGQAPKLLIYWASTLHTGVPSRFTGSGSRTDFTLTISNVQSEDLATYFCHQYSSYPFTFGQGTKLEIK
>Rivabazumab VH (threshold 0.995)
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNAKSTLYLQMNSLRAEDTAVYYCTRNRGDIYYDFTYAMDIWGQGALVTVSS
>Rivabazumab VL (threshold 0.976)
DIQMTQSPSTVSASVGDRVTITCRASEGVDRWLVWYQQKPGRAPQLLIYDASTLQSGVPSRFSGSGSGTQFSLTINSLQPDDLATYYCQHFWGTPYTFGQGTKLEIK
>Romosozumab VH (threshold 0.88)
QVQLVQSGPEVKKPGASVKIPCKASGYTFTDYNMHWVRQAHGKSLEWMGEINPNSGGAGYAQKFQGRATLTTDKSISTAYMELRSLTSEDTAVYYYARLGYDDIYDDWYFDVWGTGTTVTVSS
>Romosozumab VL (threshold 0.696)
DIQMTQTTSSLSASLGDRVTISCQASQDISNYLNWYQQKPGKAPKLLIYYTSNLLSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGDTLPYTFGQGTKLEIK
>Rontalizumab VH (threshold 0.83)
EVQLMQSGGCLVKPGWSVRMSCAASGYTFTEYIIHWVAQAPGQGLEWVSSINPDYDITNYCDSCKGRATLSRDKSKNTLYMEMSSLRAEDSAVYYCASWISDFFDYWGQGTSVTVSS
>Rontalizumab VL (threshold 0.8)
DIQLTQSPSSLAASVGDRATISCRASQSVSTSSYSYLHWYQQKPGKAPKLLIKYASSLQSGVPARFSGSGSGTDFTLNIHSLQPEDTATYYCQHSWGIPRTFGQGTRLEIK
>Rosmantuzumab VH (threshold 0.815)
QVQLVQSGPELKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYAQKFQNKATLTVDTSISTAYMELSSLTSDDTAVYFCATYFANNFDYWGQGTTLTVSS
>Rosmantuzumab VL (threshold 0.6409999999999999)
DIQLTQSPSSLSASLGDRATISCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLQSGVPARFSGSGSGTDFTLNIHPLQPEDAATYYCQQSNEDPLTFGQGTKLELK
>Rovalpituzumab VH (threshold 0.975)
QVQLVQSGGEGKKPGSTVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMAIINTYTGEPTYAQKFQGRVAMTTATSTSTAYAELSNLKSEDMAVYFCARIGDSSPSDYWGQGTTLTVSS
>Rovalpituzumab VL (threshold 0.98)
EIVMTQSPGTLSVSAGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRATGVPARFTGSGYGTDFTPTISTLQAEDFAVYFCQQDYTSPWTFGGGTKLEIK
>Ruplizumab VH (threshold 0.245)
QVQLKQSGAEVNKPGASVKLSCKASGYTFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFQSKATLTVDKSISTAYMQLSSLTSEDSAVYYCTRSDGRNDMDSWGQGTSVTVSS
>Ruplizumab VL (threshold 0.25)
DIVLTQSPATLAVSLGLRATLSCRASQRVSSSTYSYMAWYQQKPGQPPRLLIKYASNLESGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHSWEIPPTFGGGTKLEIK
>Sacituzumab VH (threshold 0.45)
QIQLVQSGYEWKKPGATVKVSCKASGYTFTNYGMNWVRQAPGKGLKWMGWINTYTGEPTYTQGFAGRFFFSLETSVSTAYLQINNLKAEDTATYFCARGGFGSSYWYFDVWGAGSTVTVSS
>Sacituzumab VL (threshold 0.716)
DIQMTQSHSFMSASVGDRVSITCRASQDVSIAVAWYQQKPGQAPKLLIYSASYLYTGVPDRFSGSGSGTDFTFTISSLQADDLAVYYCQQHYITPLTFGAGTKLEIK
>Samalizumab VH (threshold 0.355)
QVQLIQTGPELKKPGASVKISCKASGYSFTDYIILWVKQNHGKSLEWIGHIDPYYGSSNYALKFQGKATLTVDQSISTAYMELNSLTSEDSAVYYCGRSKRDYFDYWGQGTTLTVSS
>Samalizumab VL (threshold 0.489)
DIQMTQSPSSLSASIGERVTITCKASQDINSYLSWFQQKPGKSPKTLIYRANRLQDGVPSRFSGSGSGTDFSLTISSLQPEDMGIYYCLQYDEFPYTFGQGTKLEIK
>Sapelizumab VH (threshold 0.85)
QVQLQESGPGLVKPSETLSLTCTVPGHSITHDHAWSWIRQPPGEGLEWIGFISYSGITNYNPSLQGRISITVDTSKNQFSLQLNSVTAADTATYYCARSLARTTAMDYWGEGTSVTVSS
>Sapelizumab VL (threshold 0.748)
AIQMTQTTSSLSASVRDSVTITCQASTDISSHLNWYQQKPDGAPKLLIYYGSHLLSGVPSRFSGSGSGTDFTLTISNLQQEDAATYFCGQGNRLPYTFGGGTRLEIE
>Satralizumab VH (threshold 0.85)
QVQLQESGPGLVKPSETLSLTCTVPGHSITHDHAWSWIRQPPGEGLEWIGFISYSGITNYNPSLQGRISITVDTSKNQFSLQLNSVTAADTATYYCARSLARTTAMDYWGEGTSVTVSS
>Satralizumab VL (threshold 0.748)
AIQMTQTTSSLSASVRDSVTITCQASTDISSHLNWYQQKPDGAPKLLIYYGSHLLSGVPSRFSGSGSGTDFTLTISNLQQEDAATYFCGQGNRLPYTFGGGTRLEIE
>Simtuzumab VH (threshold 0.705)
QVQLVQSGAEVKRPGTSVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYAEKFQGKATLTADKSTSTAYMQLSSLTSEDTAVYFCARNWMNFDYWGQGSTLTVSS
>Simtuzumab VL (threshold 0.6)
DIVMTQSPLSLPVTPGESASISCRSSKSLLHSNGNTYLDWFLQKPGQSPQFLIYRMSNRASGVPDRFSGSGSGTAFTLRISRVEAEDVAVYYCMQHLEYPYTFGQGTKLEIK
>Sofituzumab VH (threshold 0.795)
EVQLKESGGGLVKPGGSLRLTCTVTGYSITNDYAWNWIRQAPGNKLEWMSYISYSGYTTYADSVKSRISITRDTSKNSFFLQLNSVRVEDTAVYYCARWTSGLDYWGQGTTLTVSS
>Sofituzumab VL (threshold 0.804)
DIQMTQSSSSLSASVGGRVTITCQASDLIHNWLNWYQQKPGNAPRLLISGATSLETGVPSRFSGSGSGEDFTLTIISLQPEDVATYYCQQYWTTPFTFGQGTKLEIK
>Solanezumab VH (threshold 0.855)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVSQINSVGNSTYYADTVKGRFTISRDNAKNTLYLQLSSLKTEDTAIYYCARGDYWGQGTQVTVSS
>Solanezumab VL (threshold 0.888)
DVVMTQSPLSLPVTLGQPTSISCRSSQSLIYSDGNAYLHWYLQRPGQSPELLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKLEIK
>Spartalizumab VH (threshold 0.815)
QVQLVQPGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGNIYPGTGGSNFDEKFQNKVTLTVDTSISTAYMELSSLTSEDSAVYYCTRWTTGTGAYWGQGTLVTVSA
>Spartalizumab VL (threshold 0.76)
DIVMTQSPDSLTVSPGEKATLSCKSSQSLLDSGNQKNFLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQNDYSYPYTFGGGTKLEIK
>Suvizumab VH (threshold 0.615)
QVQLIQSGAEVKRPGTSVKISCKASGYTFTNSWIGWVRQAPGHGLEWMGDIYPGGGYTNYAEIFQGKATLTADTSISTAYMQLSSLTSEDSAVYFCSRGIPGYAMDYWGQGTSVTVSS
>Suvizumab VL (threshold 0.68)
DIVMTQRPDSLSVSLGEKATMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTLTISSLQAEDLAVYYCQNDYSYPWTFGGGTKLEIK
>Tadocizumab VH (threshold 0.755)
QVQLVESGAEVKRPGTSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYAEKFQGRATLTADKSISTAYMDLSSLTSDDSAVYFCARRDGNYGWFAYWGQGTLVTVSA
>Tadocizumab VL (threshold 0.7120000000000001)
DIQMTQTTSSLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDFSLTISNLQSEDIATYFCQQGNTLPWTFGQGTRLEVK
>Talacotuzumab VH (threshold 0.815)
EVQLAQSGAEVKKPGESVKMSCKASGYTFTDYYSGWARQSHGKSLEWIGDIIPSNGATFYNQSFQGKVTLSVDKSISTTYMQWDSLKASDSAMYYCARSHLLRASWFAYWGQGTLVTVSA
>Talacotuzumab VL (threshold 0.935)
DIVMTQSPDSLAVSLGERASINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK
>Tanezumab VH (threshold 0.855)
QVQLQEWGAGLVAPSEPLSATCTVSGFSLTGYDWNWIRQPPGKGLEWIGIIWGDGTTDYNPSVKSRVSISVDNSKSQVTLKLTSVTAADTARYYCARGGYWYATSYYFDYWGQGTTLTVSS
>Tanezumab VL (threshold 0.8859999999999999)
DIQMTQSTSSLSASLGDRVTITCQASQSISNNLNWYQQKPGKAPKLLIYYTSNFHSGVPSRFSGSGSGTDFSFTISNLQPEDIATYFCQQEHTLPYTFGQGTKLEIK
>Telisotuzumab VH (threshold 1.0)
QVQLIQSGAEVKKPGSSVKVSCKTSGYTFTAYTAHWVRQAHGKSLEWMGWIKPNNGLANYAQKFQGAVTLTRDKSISTAYMELLSLTSEDTAVYYCARSEITTEFDYWGQGTTLTVSS
>Telisotuzumab VL (threshold 0.92)
DIVLTQSPDSLAVSLGDRATINCKSSESVDSYANSFLAWYQQKPGQPPKLLIYRASTRESGIPDRFSGSGSRTDFTLTINSLQADDVATYYCQQSKEDPLTFGAGTKVEIK
>Teplizumab VH (threshold 0.695)
QVQLQQSGGGLARPGASLRMSCAASGYTFTRYTMHWVRQAPGQGLEWISYINPSRGYTNYAQSVKDRFTLSRDKSSSTAYMQMSSLTVEDSAVYYCARYYDDHYCLDYWGQGTPVTVSS
>Teplizumab VL (threshold 0.716)
DIQMTQSTSSLSVSAGERVTITCSASSSVSYLNWYQQTSGTAPKRWIYDTSKLQSGVPARFSGSGSGTSFSLTISSMQPEDAATYYCQQWSSNPFTFGQGTKLQIT
>Tibulizumab VH (threshold 1.0)
QVQLQESGPGLVKPSETLSLTCAVSGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISTDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGVLVTVSS
>Tibulizumab VL (threshold 1.0)
DIVLTQSPATASLSPGEKATLTCRASQSVSRYLAWYQQKPGQSPRLRIYDASNRATGVPARFSGSGSGTDSSLTISSAEAEDFASYFCQQRSNWPRTFGGGTKLEIK
>Tigatuzumab VH (threshold 0.85)
QVQLVESGGGVVKPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVAVISSGGSYTYYADSVKGRFTISRDNAKNTLYLQMSSLRVEDTAVYYCARRGDSMITTDYWGQGTTLTVSS
>Tigatuzumab VL (threshold 0.8420000000000001)
DIQMTQSPSFMSTSVGDRVSITCRASQDVGTAVAWYQQKPGQAPKLLIYWASTLHTGVPSRFTGSGSGTDFTLTISNLQPDDLATYFCQQYSSYRTFGGGTKLEIK
>Tildrakizumab VH (threshold 0.9)
QVQLEQSGPEVKRPGASVKLSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYAEKFQGRVTLTVDTSISTAYMDLSSLRSEDSAVYYCARGGGGFAYWGQGTLVTVSS
>Tildrakizumab VL (threshold 0.522)
DIQMTQSPASLSAFVGERVTITCRTSENIYSYLNWYQQKQGKAPQFLVYNAKTLQEGVPSRFSGSGSGTQFSLTINSLQPEDFGSYYCQHHYGIPFTFGQGTKLEIK
>Timigutuzumab VH (threshold 0.965)
EVQLMESGGALVAPGGSLRLSCTASGFNIKDTYIHWVRQAPGQGLEWISRIYPTNGYTRYADSVKGRCTISRDTSSNTAYLQMSSLRVEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
>Timigutuzumab VL (threshold 0.777)
DIMMTQSHSFMSTSVGDRVSITCRASQDVNTAVNWYQQKPGHAPKLLIYSASFLYSGVPSRFTGSRSGTDFTFTINSLQAEDLATYYCQQHYTTPPTFGGGTKLEIK
>Tislelizumab VH (threshold 0.845)
QVQLQEWGPGLVAPSETLSLTCTVSGFSLTSYGWHWVRQPPGKGLEWIGVIYADGSTNYNPSLKSRVSISVDNSKSQVSLKMNSVTAADTAMYYCARAYGNYWYIDVWGAGTTVTVSS
>Tislelizumab VL (threshold 0.905)
DIVMTQTPDFLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRESGVPARFTGSGYGTDFTLTISTLQAEDVAVYFCHQAYSSPYTFGGGTKLEIK
>Tocilizumab VH (threshold 0.935)
QVQLQESGPGLVKPSETLSLTCTVSGYSITSDHAWSWIRQAPGKGLEWIGYISYSGITTYNPSLKSRISILVDTSKNQFSLKLNSVTTADTAVYYCARSLARTTAMDYWGQGSLVTVSS
>Tocilizumab VL (threshold 0.65)
DIQMTQTTSSLSASVGDRVTISCRASQDISSYLNWYQQKPDKAPKLLIYYTSRLQSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGNTLPYTFGQGTRLEIK
>Trastuzumab VH (threshold 0.965)
EVQLMESGGALVAPGGSLRLSCTASGFNIKDTYIHWVRQAPGQGLEWISRIYPTNGYTRYADSVKGRCTISRDTSSNTAYLQMSSLRVEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
>Trastuzumab VL (threshold 0.777)
DIMMTQSHSFMSTSVGDRVSITCRASQDVNTAVNWYQQKPGHAPKLLIYSASFLYSGVPSRFTGSRSGTDFTFTINSLQAEDLATYYCQQHYTTPPTFGGGTKLEIK
>Tregalizumab VH (threshold 0.93)
EEQLVETGGGLVRPGGSLRLSCVASGFTFSDCRMYWLRQAPGKRLVWVSVISVKSENYGANYAESVRGRFTISRDDSKNSVYLQMNSLREEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS
>Tregalizumab VL (threshold 0.855)
DIVLTQSPDSLAVSLGQRATINCRSSKSVSTSGYSYIYWYQQKPGQPPKLLIYLASIRESGVPDRFSGSGSGTDFTLTISPLQEEDVAVYYCQHSRELPWTFGGGTKLEIK
>Vandortuzumab VH (threshold 0.8)
EVQLKESGGGLVKPGGSLRLTCTVSGYSITSDYAWNWIRQAPGKGLEWMSYISNSGSTSYADSLKGRISITRDNSKNSFFLQLNSVTTEDTALYYCARERNYDYDDYYYAMDYWGQGTSVTVSS
>Vandortuzumab VL (threshold 0.725)
DIQMTQSPSSLSASVGDRVTMSCRSSQSLLYRSNQKNYLNWYQQKPGKAPKLLIYWASTLESGVPSRFTGSGSGTEFTLTISSLKPEDFATYYCQQYYNYPRTFGGGTKLEIK
>Vatelizumab VH (threshold 0.595)
QVQLQEWGAGLVKPSETLSITCTVSGFSLTNYGWHWIRQPPGKGLEWIGVIWARGFTNYNSALMSRLSISVDNSKSQVSLKMNSLTTADTAMYYCARANDGVYYAMDYWGQGTSVTVSS
>Vatelizumab VL (threshold 0.268)
DFVMTQSPAIQSASPKEKVTITCSAQSSVNYIHWYQQKSDTSPKKWIKDTSKLFSGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWTTNPLTFGAGTKLELK
>Vedolizumab VH (threshold 0.795)
QVQLVQPGAEVKKPGASVKLSCKASGYTFTSYWMHWVRQAPGQGLEWMGEIDPSESNTNYAQKFQGKATLTWDISMSTAYMELSSLTSEDSAVYYCARGGYDGWDYAIDYWGQGTSVTVSS
>Vedolizumab VL (threshold 0.83)
DVVVTQTPLSLSVTPGQQASISCKSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRLKAEDVGMYYCLQGTHQPYTFGQGTKLEIK
>Veltuzumab VH (threshold 0.415)
QVQLQQPGAELKKPGASVKMSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYAQKFQGKATLTADKSISTAYMELSSLTSEDSAFYYCARSTYYGGDWYFDVWGAGTTVTVSS
>Veltuzumab VL (threshold 0.6990000000000001)
DIQLTQSPSILSASVGERVTMTCRASSSVSYIHWYQQKPGSAPKPWIYATSNLQSGVPVRFSGSGSGTSFSLTISSMQPEDAATYYCQQWTSNPPTFGQGTKLEIK
>Visilizumab VH (threshold 0.685)
QVQLVQSGAEVNKPGASVKVSCKASGYTFTSYTMHWVRQAPGQGLEWIGYINPRSGYTHYAQKLQDRATLTWDKSMSTAYMQLSSLTYEDSAVYYCARSAYYDYDGFAYWGQGTLVTVSA
>Visilizumab VL (threshold 0.848)
DIQLTQTPSSLSASVGDRVTMTCRASSSVSYLNWYQQKSGTAPKRLIYDTSKLQSGVPARFSGSGSGTSFSLTISSLQPEDAATYYCQQWSSNPPTFGGGTKLEIK
>Vonlerolizumab VH (threshold 0.825)
QLQLVQSGPEVKEPGASMKVSCKASGYTFTDSYMSGVRQSHGKSLEWMGDMYPDNGDSSYAQKFQESATLTVDRSISTAYMELDSLTSEDTAAHYCVLAPRWYFSVWGAGTTVTVSS
>Vonlerolizumab VL (threshold 0.674)
DIQMTQTPSSLSASLGDRVTISCRASQDISNYLNWYQQKPGKAPKLLIYYTSNLRSGVPSRFSGSGSGTDFSLTISNLQQEDIATYFCQQGHTLPPTFGQGTKLEIK
>Vorsetuzumab VH (threshold 0.965)
QGQLVQSGAAVKKPGSSVKVSCKASGYTFTNYGINWVRQAPGNGLKWMGWINTYTGEPTYAQKFKGRVAMTTDTSIDTAYLDLCNLRNEDTAVYFCARDYGDYGMDYWGQGTSVTVSS
>Vorsetuzumab VL (threshold 0.7)
DIVLTQSPDSLAVSLGQRATINCRSSKSVSTSGYSFLAWYQQKPGQPPKLLIYLASTRESGVPARFSGSGSGTDFTLNIHSVQEEDAAVYYCQHSREVPWTFGGGTKLEIK
>Vunakizumab VH (threshold 0.91)
EVQVVQSGAEVKRPGASVTVSCKASGYTFTDYEVHWVRQAPVHGLEWLGVIDPGTGGVAYAQKFEGRVILTADKSISPAYLELRSLTSEDTAVYYCTRYSLFYGSSPYAMDYWGQGTSVTVSS
>Vunakizumab VL (threshold 0.605)
EIVITQTTDIQSASPKEKVTITCRASSSVNYMHWYQQKSDASPKPWIKRTSQSASGVPARFSGSGSGTSFTLTISRLEAEDAATYYCQQRSSYPWTFGGGTKLEIK
>Zenocutuzumab VH (threshold 1.0)
QVQLIQSGPEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQSLEWMGWINPNSGGTNYAQKFQGRLTLTADKSSSTAYMELRSLTSEDTAVYYCARDHGSRHFWSYWGFDYWGTGTTVTVSS
>Zenocutuzumab VL (threshold 1.0)
DIQLTQSPPTLSAAVGDRVSISCRASQSISSYLNWYQQKSGEAPRLLIYAASSLQSGVPSRFSGSGSGTDFTLSINSLQPEDFGTYFCQQSYSTPPTFGQGTKLEAK
